HealthTree Foundation is collaborating with several multiple myeloma specialists (see below) and the International Myeloma Society for a three-year bispecific antibody study, and you are invited to participate! It is critical for the myeloma research community to know how this treatment is optimally being used and for whom.

This study is open to any myeloma patient receiving bispecific antibody treatment. This treatment may have been received through participation in a clinical trial, compassionate use program, or as a commercially available (FDA-approved) treatment.

The study consists of 8 surveys designed to gather information about patient experience with specifics, ranging from initial awareness to quality of life after at least four months of treatment.

The eight surveys (8-19 questions each) cover topics such as treatment decision-making, side effects, outcomes, caregiver involvement, financial aspects, and quality of life. You will not be required to complete all 8 surveys at once. Instead, you will be asked to complete them over several weeks or months, depending on your treatment timeline.

CLICK HERE TO PARTICIPATE

The information you submit is protected and private and will be shared anonymously with researchers. We value your privacy and are grateful for your contributions.

Research Partners

Contact Information: If you have any questions or concerns about the study, you can contact our HealthTree Patient Navigators (email support@healthtree.org or call +1 800 709 1113).